$20.58
Live
1.02%
Downside
Day's Volatility :2.25%
Upside
1.25%
36.05%
Downside
52 Weeks Volatility :39.33%
Upside
5.12%
Period | Bausch + Lomb Corp. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 19.25% | 3.6% | 0.0% |
6 Months | 40.92% | 10.2% | 0.0% |
1 Year | 26.18% | 19.6% | 0.0% |
3 Years | 3.15% | 16.8% | -23.0% |
Market Capitalization | 7.3B |
Book Value | $18.49 |
Earnings Per Share (EPS) | -1.29 |
PEG Ratio | 0.7 |
Wall Street Target Price | 27.56 |
Profit Margin | -10.15% |
Operating Margin TTM | 3.04% |
Return On Assets TTM | 0.96% |
Return On Equity TTM | -6.5% |
Revenue TTM | 4.5B |
Revenue Per Share TTM | 12.8 |
Quarterly Revenue Growth YOY | 17.5% |
Gross Profit TTM | 2.2B |
EBITDA | 607.0M |
Diluted Eps TTM | -1.29 |
Quarterly Earnings Growth YOY | -0.89 |
EPS Estimate Current Year | 0.84 |
EPS Estimate Next Year | 1.18 |
EPS Estimate Current Quarter | 0.17 |
EPS Estimate Next Quarter | 0.22 |
What analysts predicted
Upside of 33.92%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.7B | - |
Net Income | 710.0M | - |
Net Profit Margin | 19.37% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 3.8B | ↑ 3.08% |
Net Income | 298.0M | ↓ 58.03% |
Net Profit Margin | 7.89% | ↓ 11.48% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.4B | ↓ 9.69% |
Net Income | -17.0M | ↓ 105.7% |
Net Profit Margin | -0.5% | ↓ 8.39% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.8B | ↑ 10.35% |
Net Income | 182.0M | ↓ 1170.59% |
Net Profit Margin | 4.83% | ↑ 5.33% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.8B | ↑ 0.08% |
Net Income | 15.0M | ↓ 91.76% |
Net Profit Margin | 0.4% | ↓ 4.43% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.1B | ↑ 10.03% |
Net Income | -260.0M | ↓ 1833.33% |
Net Profit Margin | -6.27% | ↓ 6.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 931.0M | ↓ 6.53% |
Net Income | -88.0M | ↑ 8700.0% |
Net Profit Margin | -9.45% | ↓ 9.35% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↑ 11.17% |
Net Income | -32.0M | ↓ 63.64% |
Net Profit Margin | -3.09% | ↑ 6.36% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 2.71% |
Net Income | -84.0M | ↑ 162.5% |
Net Profit Margin | -8.34% | ↓ 5.25% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.2B | ↑ 16.48% |
Net Income | -54.0M | ↓ 35.71% |
Net Profit Margin | -4.6% | ↑ 3.74% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↓ 6.31% |
Net Income | -167.0M | ↑ 209.26% |
Net Profit Margin | -15.2% | ↓ 10.6% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.2B | ↑ 10.65% |
Net Income | -151.0M | ↓ 9.58% |
Net Profit Margin | -12.42% | ↑ 2.78% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 11.5B | - |
Total Liabilities | 1.4B | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 11.3B | ↓ 1.76% |
Total Liabilities | 1.3B | ↓ 11.0% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 10.8B | ↓ 3.93% |
Total Liabilities | 1.4B | ↑ 11.19% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 11.1B | ↑ 2.97% |
Total Liabilities | 4.0B | ↑ 184.52% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 13.4B | ↑ 20.62% |
Total Liabilities | 6.5B | ↑ 61.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.2B | ↑ 0.22% |
Total Liabilities | 4.1B | ↑ 1.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.3B | ↑ 1.31% |
Total Liabilities | 4.3B | ↑ 4.08% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.1B | ↑ 15.49% |
Total Liabilities | 6.2B | ↑ 44.34% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.4B | ↑ 2.86% |
Total Liabilities | 6.5B | ↑ 5.45% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 13.3B | ↓ 1.11% |
Total Liabilities | 6.6B | ↑ 0.64% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 13.3B | ↓ 0.32% |
Total Liabilities | 6.7B | ↑ 1.61% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 763.0M | - |
Investing Cash Flow | -74.0M | - |
Financing Cash Flow | -665.0M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 799.0M | ↑ 4.72% |
Investing Cash Flow | -186.0M | ↑ 151.35% |
Financing Cash Flow | -606.0M | ↓ 8.87% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 522.0M | ↓ 34.67% |
Investing Cash Flow | -256.0M | ↑ 37.63% |
Financing Cash Flow | -232.0M | ↓ 61.72% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 873.0M | ↑ 67.24% |
Investing Cash Flow | -214.0M | ↓ 16.41% |
Financing Cash Flow | -712.0M | ↑ 206.9% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 345.0M | ↓ 60.48% |
Investing Cash Flow | -215.0M | ↑ 0.47% |
Financing Cash Flow | 81.0M | ↓ 111.38% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -56.0M | ↓ 135.22% |
Investing Cash Flow | -64.0M | ↓ 28.89% |
Financing Cash Flow | 91.0M | ↓ 1400.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.0M | ↓ 57.14% |
Investing Cash Flow | -28.0M | ↓ 56.25% |
Financing Cash Flow | 90.0M | ↓ 1.1% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 48.0M | ↓ 300.0% |
Investing Cash Flow | -1.9B | ↑ 6621.43% |
Financing Cash Flow | 1.8B | ↑ 1912.22% |
Sell
Neutral
Buy
Bausch + Lomb Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Bausch + Lomb Corp. | 5.9% | 40.92% | 26.18% | 3.15% | 3.15% |
Intuitive Surgical, Inc. | 6.56% | 41.26% | 91.18% | 53.45% | 177.85% |
Resmed Inc. | -2.51% | 33.07% | 63.68% | -8.76% | 83.88% |
Becton, Dickinson And Company | 3.84% | 4.22% | -4.76% | -1.1% | -4.07% |
Alcon Ag | -2.89% | 18.03% | 30.76% | 16.68% | 62.63% |
Cooper Companies Inc., The | -1.41% | 20.24% | -66.42% | 5.22% | 50.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Bausch + Lomb Corp. | 914.0 | NA | 0.7 | 0.84 | -0.06 | 0.01 | NA | 18.49 |
Intuitive Surgical, Inc. | 81.54 | 81.54 | 4.08 | 6.65 | 0.16 | 0.08 | NA | 41.4 |
Resmed Inc. | 34.67 | 34.67 | 2.0 | 7.71 | 0.23 | 0.13 | 0.01 | 33.11 |
Becton, Dickinson And Company | 48.07 | 48.07 | 1.11 | 13.11 | 0.06 | 0.03 | 0.02 | 89.5 |
Alcon Ag | 42.58 | 42.58 | 3.58 | 3.06 | 0.05 | 0.03 | 0.0 | 42.35 |
Cooper Companies Inc., The | 59.32 | 59.32 | 11.0 | 3.66 | 0.05 | 0.03 | NA | 39.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Bausch + Lomb Corp. | Buy | $7.3B | 3.15% | 914.0 | -10.15% |
Intuitive Surgical, Inc. | Buy | $168.3B | 177.85% | 81.54 | 27.65% |
Resmed Inc. | Buy | $35.2B | 83.88% | 34.67 | 21.79% |
Becton, Dickinson And Company | Buy | $69.5B | -4.07% | 48.07 | 7.13% |
Alcon Ag | Buy | $46.6B | 62.63% | 42.58 | 11.44% |
Cooper Companies Inc., The | Buy | $21.3B | 50.71% | 59.32 | 9.45% |
Insights on Bausch + Lomb Corp.
Revenue is up for the last 2 quarters, 1.09B → 1.21B (in $), with an average increase of 9.6% per quarter
Netprofit is up for the last 2 quarters, -167.0M → -151.0M (in $), with an average increase of 10.6% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 95.3% return, outperforming this stock by 73.3%
Fidelity International Ltd
Goldentree Asset Management LP
Maple Rock Capital Partners, Inc.
ICAHN CARL C
River Road Asset Management, LLC
Alberta Investment Management Corp
bausch and lomb corp is a renewables and environment company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Organization | Bausch + Lomb Corp. |
Employees | 13000 |
CEO | Mr. Brenton L. Saunders J.D. |
Industry | Healthcare |
Surgery Partners Inc
$20.58
-0.24%
Geron Corporation
$20.58
-0.24%
Acadia Pharmaceuticals Inc.
$20.58
-0.24%
Springworks Therapeutics Inc
$20.58
-0.24%
Radnet Inc
$20.58
-0.24%
Penumbra Inc
$20.58
-0.24%
Hutchison China Meditech Limited
$20.58
-0.24%
Krystal Biotech Inc
$20.58
-0.24%
Amn Healthcare Services Inc.
$20.58
-0.24%